The Analysis of The Effectiveness of Pulmonary Tuberculosis and HIV-Co-TB Treatment Therapies at Sulianti Saroso Infectious Diseases Hospital

  • Nurita Andayani Faculty of Pharmacy, Universitas Pancasila, South Jakarta 12640, Indonesia
  • Raise Maninda Faculty of Pharmacy, Universitas Pancasila, South Jakarta 12640, Indonesia
  • Rosa Marlina Department of Pulmonology and Respiratory Medicine, Sulianti Saroso Infectious Disease Hospital, North Jakarta 14340 Indonesia
  • Qoina Noviantani Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta 12640, Indonesia
  • Khaled Qalalwa Palestinian Central Bureau of Statistics, Ramallah, Palestine, Higher Council for Innovation & Excellence (HCIE), Palestine
DOI: https://doi.org/10.35814/jifi.v21i2.1282

Abstract

Mycobacterium tuberculosis causes Tuberculosis (TB), an infectious disease. The study aims to evaluate DOTS therapy's impact on pulmonary TB and TB-HIV patients. This research used a descriptive qualitative study design with a retrospective descriptive research approach using secondary  data for the period June 2017 to July 2020. The analysis uses the Miles and Huberman model. A study of 305 people found that 83% of pulmonary TB cases completed treatment within the initial phase, 64% completed the continuation phase. TB-HIV cases 93% completed treatment within the initial phase, 71% the continuation phase. The combination of OAT and ARV doses was successful in reducing initial smear conversion in pulmonary TB cases. The treatment was evaluated as cure in pulmonary TB cases, complete in pulmonary TB-HIV cases, and had no treatment failure status in both groups. Treatment success in pulmonary TB patients was not significantly related (p-value≥5%) with the type of OAT, type of PMO, gender, and age. Whereas in HIV co-infected pulmonary TB patients, treatment success was significantly related (p-value <5%) with the type of PMO, and not related (p-value≥5%) with the type of OAT, gender, and age.

References

1. Bagcchi S. WHO's global tuberculosis report 2022. The Lancet Microbe. 2023;4(1):e20.

2. Kayukova LA, Berikova EA. Modern anti-tuberculosis drugs and their classification. Part I: first-line drugs. Pharmaceutical Chemistry Journal. 2020;54:555-63.

3. Ministry of Health of Republic of Indonesia. Profil kesehatan Indonesia tahun 2021. Jakarta; 2022.

4. Ministry of Health of Republic of Indonesia. Strategi nasional penanggulangan tuberkulosis di Indonesia 2020-2024. Jakarta; 2020.

5. Ji YJ, Liang PP, Shen JY, Sun JJ, Yang JY, Chen J, Qi TK, Wang ZY, Song W, Tang Y, Liu L. Risk factors affecting the mortality of HIV-infected patients with pulmonary tuberculosis in the cART era: a retrospective cohort study in China. Infectious diseases of poverty. 2018;7:1-9.

6. Putra KW, Toonsiri C. Factors related to the successful treatment of tuberculosis: A literature review. Belitung Nursing Journal. 2019;5(4):136-46.

7. Dailami FA, Wiraharja RS, Chriestya FC. Relationship between successful treatment of pulmonary tuberculosis patients with the availability of treatment supporter in Atma Jaya Hospital. Damianus Journal of Medicine. 2019 Nov 15;18(2):67-73. Reyne, S. K. 2004.

8. Adams LE, Waterman S, Paz-Bailey G. Vaccination for dengue prevention. Jama. 2022;327(9):817-8.

9. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nature Reviews Microbiology. 2022;20(11):685- 701.

10. Asrifuddin A. Analisis capaian keberhasilan pengobatan TB paru (treatment succes rate) di puskesmas Ranotana Weru kota Manado.. Kesmas: Jurnal Kesehatan Masyarakat Universitas Sam Ratulangi. 2018;7(1):69-76.

11. Fitri, Lili Diana. Kepatuhan Minum Obat Pada Pasien Tuberkulosis Paru. Jurnal Ilmu Kesehatan Masyarakat. 2018. 33–42.

12. Ministry of Health of Republic of Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuber-kulosis. Jakarta. 2016.

13. Cahyawati F. Tatalaksana Tb pada Orang dengan Hiv/aids (ODHA). Cermin Dunia Kedokteran. 2018;45(9):704-8.

14. Konde CP, Asrifuddin A, Langi FL. Hubungan antara umur, status gizi dan kepadatan hunian dengan tuber-kulosis paru di Puskesmas Tuminting Kota Manado. KESMAS: Jurnal Kesehatan Masyarakat Universitas Sam Ratulangi. 2020;9(1):106-13.

15. Ministry of Health of Republic of Indonesia. Keputusan kenteri kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/755/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. 2019.

16. Apay, F. and Rohmani, R. Factors affecting the success of treatment in drug sensitive pulmonary tuberculosis patients at the Rimba Jaya health center Merauke regency, Science Midwifery, 10(4). 2022. Type of pp. 2992-3000. doi: 10.35335/midwifery.v10i4.740.

17. Yusmaniar Y, Kurniawan AH. Medication Adherence to Successful Tuberculosis Treatment Outcome among TB/HIV Patient at Prof. Dr. Sulianti Saroso Infectious Disease Hospital. Pharmacology and Clinical Pharmacy Research. 2020;5(3):98-105.
Published
2023-10-16
How to Cite
ANDAYANI, Nurita et al. The Analysis of The Effectiveness of Pulmonary Tuberculosis and HIV-Co-TB Treatment Therapies at Sulianti Saroso Infectious Diseases Hospital. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 21, n. 2, p. 193-200, oct. 2023. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1282>. Date accessed: 27 apr. 2024. doi: https://doi.org/10.35814/jifi.v21i2.1282.
Citation Formats
Issue
Vol 21 No 2 (2023): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.